Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

15 août 2024 12h13 HE | Source: OKYO Pharma LTD

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
06 août 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
11 juil. 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
10 juil. 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...
25 juin 2024 10h03 HE | Source: Research and Markets

Allergic Conjunctivitis Market Research 2024-2032 with Focus on North America

Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Global Allergic Conjunctivitis Market Report by Disease Type, Drug class, Distribution Channel, Countries and Company Analysis, 2024-2032" report has...
08 mai 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Announces Participation in May 2024 Investor Conferences

LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
30 avr. 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
25 avr. 2024 07h28 HE | Source: Research and Markets

Global Scleral Lens Market Outlook 2023-2035: Market is Forecast to Garner Revenue of USD 0.87 billion by 2035, Up from USD 0.31 Billion in 2022

Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Global Scleral Lens Market Outlook 2023-2035" report has been added to ResearchAndMarkets.com's offering.In an industry analysis of the global...
02 avr. 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
22 mars 2024 07h00 HE | Source: OKYO Pharma LTD

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief

Page précédente

Page suivante